



## Clinical trial results:

### A Randomized Phase 2 Study Evaluating Abiraterone Acetate With Different Steroid Regimens for Preventing Symptoms Associated With Mineralocorticoid Excess in Asymptomatic, Chemotherapy-Naive and Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients

#### Summary

EudraCT number	2012-004331-23
Trial protocol	DE BE GB IT HU
Global end of trial date	05 June 2018

#### Results information

Result version number	v1 (current)
This version publication date	21 June 2019
First version publication date	21 June 2019

#### Trial information

##### Trial identification

Sponsor protocol code	CR100916
-----------------------	----------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01867710
WHO universal trial number (UTN)	-

Notes:

##### Sponsors

Sponsor organisation name	Janssen-Cilag International NV
Sponsor organisation address	Turnhoutseweg 30, Beerse, Belgium, 2340
Public contact	Clinical Registry Group, Janssen-Cilag International NV, ClinicalTrialsEU@its.jnj.com
Scientific contact	Clinical Registry Group, Janssen-Cilag International NV, ClinicalTrialsEU@its.jnj.com

Notes:

##### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	05 June 2018
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	05 June 2018
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

The main objective of this study was to evaluate the safety of abiraterone acetate with 4 alternative steroid treatment strategies related to symptoms associated with mineralocorticoid excess toxicities (i.e, hypokalemia and/or hypertension) during the first 24 weeks of treatment in asymptomatic, chemotherapy-naïve, mCRPC (metastatic castration-resistant prostate cancer) subjects.

Protection of trial subjects:

This study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with Good Clinical Practices and applicable regulatory requirements. Safety evaluations included adverse events (AEs), clinical laboratory tests (insulin resistance, lipids, ACTH [adrenocorticotrophic hormone], serum androgens, urinary steroid excretion, hematology, and serum chemistry, urinalysis), vital sign measurements, dual-energy x-ray absorptiometry (DXA) scans, physical examinations.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	28 June 2013
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Belgium: 41
Country: Number of subjects enrolled	Germany: 28
Country: Number of subjects enrolled	United Kingdom: 35
Country: Number of subjects enrolled	Hungary: 20
Country: Number of subjects enrolled	Italy: 40
Worldwide total number of subjects	164
EEA total number of subjects	164

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23	0

months)	
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	40
From 65 to 84 years	118
85 years and over	6

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

Of the 204 subjects who were enrolled, 39 were screen failures and 1 subject withdrew consent before randomization. A total of 164 subjects were randomized to prednisone 5 milligram (mg) BID (41 subjects), prednisone 5 mg QD (41 subjects), prednisone 2.5 mg BID (40 subjects), and dexamethasone 0.5 mg (42 subjects) QD groups.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Abiraterone Acetate 1000 mg QD + Prednisone 5 mg BID

Arm description:

Subjects received abiraterone acetate 1000 milligram (mg) tablet orally once daily (QD) and prednisone 5 mg tablet orally twice daily (BID) up to 156 Weeks. Subjects who were progression-free at 156 weeks entered the extension phase of the study and received study treatment until death, radiographic disease progression and/or unequivocal clinical progression, and/or other specific reasons for discontinuation. Subjects who ended the extension phase prematurely and subjects who did not enter the extension phase entered a follow-up phase until end of study.

Arm type	Experimental
Investigational medicinal product name	Abiraterone Acetate
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received abiraterone acetate 1000 mg QD up to 156 weeks. Subjects who were progression-free at 156 weeks entered the extension phase of the study and received study treatment until death, radiographic disease progression and/or unequivocal clinical progression, and/or other specific reasons for discontinuation.

Investigational medicinal product name	Prednisone
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received prednisone 5 mg BID up to 156 weeks. Subjects who were progression-free at 156 weeks entered the extension phase of the study and received study treatment until death, radiographic disease progression and/or unequivocal clinical progression, and/or other specific reasons for discontinuation.

<b>Arm title</b>	Abiraterone Acetate 1000 mg QD + Prednisone 5 mg QD
------------------	---

Arm description:

Subjects received abiraterone acetate 1000 mg and prednisone 5 mg tablet orally QD up to 156 Weeks. Subjects who were progression-free at 156 weeks entered the extension phase of the study and received study treatment until death, radiographic disease progression and/or unequivocal clinical progression, and/or other specific reasons for discontinuation. Subjects who ended the extension phase prematurely and subjects who did not enter the extension phase entered a follow-up phase until end of study.

Arm type	Experimental
Investigational medicinal product name	Abiraterone Acetate
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

**Dosage and administration details:**

Subjects received abiraterone acetate 1000 mg QD up to 156 weeks. Subjects who were progression-free at 156 weeks entered the extension phase of the study and received study treatment until death, radiographic disease progression and/or unequivocal clinical progression, and/or other specific reasons for discontinuation.

Investigational medicinal product name	Prednisone
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

**Dosage and administration details:**

Subjects received prednisone 5 mg QD up to 156 weeks. Subjects who were progression-free at 156 weeks entered the extension phase of the study and received study treatment until death, radiographic disease progression and/or unequivocal clinical progression, and/or other specific reasons for discontinuation.

<b>Arm title</b>	Abiraterone Acetate 1000 mg QD + Prednisone 2.5 mg BID
------------------	--

**Arm description:**

Subjects received abiraterone acetate 1000 mg tablet orally QD and prednisone 2.5 mg tablet orally BID up to 156 Weeks. Subjects who were progression-free at 156 weeks entered the extension phase of the study and received study treatment until death, radiographic disease progression and/or unequivocal clinical progression, and/or other specific reasons for discontinuation. Subjects who ended the extension phase prematurely and subjects who did not enter the extension phase entered a follow-up phase until end of study.

Arm type	Experimental
Investigational medicinal product name	Prednisone
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

**Dosage and administration details:**

Subjects received prednisone 2.5 mg BID up to 156 weeks. Subjects who were progression-free at 156 weeks entered the extension phase of the study and received study treatment until death, radiographic disease progression and/or unequivocal clinical progression, and/or other specific reasons for discontinuation.

Investigational medicinal product name	Abiraterone Acetate
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

**Dosage and administration details:**

Subjects received abiraterone acetate 1000 mg QD up to 156 weeks. Subjects who were progression-free at 156 weeks entered the extension phase of the study and received study treatment until death, radiographic disease progression and/or unequivocal clinical progression, and/or other specific reasons for discontinuation.

<b>Arm title</b>	Abiraterone Acetate 1000 mg QD + Dexamethasone 0.5 mg QD
------------------	--

**Arm description:**

Subjects received abiraterone acetate 1000 mg and dexamethasone 0.5 mg tablet orally QD up to 156 Weeks. Subjects who were progression-free at 156 weeks entered the extension phase of the study and received study treatment until death, radiographic disease progression and/or unequivocal clinical progression, and/or other specific reasons for discontinuation. Subjects who ended the extension phase prematurely and subjects who did not enter the extension phase entered a follow-up phase until end of

study.

Arm type	Experimental
Investigational medicinal product name	Dexamethasone
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received dexamethasone 0.5 mg QD up to 156 weeks. Subjects who were progression-free at 156 weeks entered the extension phase of the study and received study treatment until death, radiographic disease progression and/or unequivocal clinical progression, and/or other specific reasons for discontinuation.

Investigational medicinal product name	Abiraterone Acetate
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received abiraterone acetate 1000 mg QD up to 156 weeks. Subjects who were progression-free at 156 weeks entered the extension phase of the study and received study treatment until death, radiographic disease progression and/or unequivocal clinical progression, and/or other specific reasons for discontinuation.

<b>Number of subjects in period 1</b>	Abiraterone Acetate 1000 mg QD + Prednisone 5 mg BID	Abiraterone Acetate 1000 mg QD + Prednisone 5 mg QD	Abiraterone Acetate 1000 mg QD + Prednisone 2.5 mg BID
Started	41	41	40
Treated	41	41	39
Completed	0	0	0
Not completed	41	41	40
Clinical progression	-	-	1
Disease progression	1	-	-
Study terminated by sponsor	9	13	8
Patient to follow subsequent treatment	-	1	-
Consent withdrawn by subject	2	5	1
Patient decision	-	-	-
Death	25	15	27
Study medication no longer effective	-	1	-
PSA-progression	-	1	-
Progressive disease	1	-	-
Lost to follow-up	3	4	3
Biochemical progression	-	1	-
Protocol deviation	-	-	-

<b>Number of subjects in period 1</b>	Abiraterone Acetate 1000 mg QD + Dexamethasone 0.5 mg QD
Started	42
Treated	42
Completed	0
Not completed	42
Clinical progression	-
Disease progression	-
Study terminated by sponsor	16
Patient to follow subsequent treatment	-
Consent withdrawn by subject	2
Patient decision	1
Death	20
Study medication no longer effective	-
PSA-progression	-
Progressive disease	-
Lost to follow-up	2
Biochemical progression	-
Protocol deviation	1

## Baseline characteristics

### Reporting groups

Reporting group title	Abiraterone Acetate 1000 mg QD + Prednisone 5 mg BID
-----------------------	--

#### Reporting group description:

Subjects received abiraterone acetate 1000 milligram (mg) tablet orally once daily (QD) and prednisone 5 mg tablet orally twice daily (BID) up to 156 Weeks. Subjects who were progression-free at 156 weeks entered the extension phase of the study and received study treatment until death, radiographic disease progression and/or unequivocal clinical progression, and/or other specific reasons for discontinuation. Subjects who ended the extension phase prematurely and subjects who did not enter the extension phase entered a follow-up phase until end of study.

Reporting group title	Abiraterone Acetate 1000 mg QD + Prednisone 5 mg QD
-----------------------	---

#### Reporting group description:

Subjects received abiraterone acetate 1000 mg and prednisone 5 mg tablet orally QD up to 156 Weeks. Subjects who were progression-free at 156 weeks entered the extension phase of the study and received study treatment until death, radiographic disease progression and/or unequivocal clinical progression, and/or other specific reasons for discontinuation. Subjects who ended the extension phase prematurely and subjects who did not enter the extension phase entered a follow-up phase until end of study.

Reporting group title	Abiraterone Acetate 1000 mg QD + Prednisone 2.5 mg BID
-----------------------	--

#### Reporting group description:

Subjects received abiraterone acetate 1000 mg tablet orally QD and prednisone 2.5 mg tablet orally BID up to 156 Weeks. Subjects who were progression-free at 156 weeks entered the extension phase of the study and received study treatment until death, radiographic disease progression and/or unequivocal clinical progression, and/or other specific reasons for discontinuation. Subjects who ended the extension phase prematurely and subjects who did not enter the extension phase entered a follow-up phase until end of study.

Reporting group title	Abiraterone Acetate 1000 mg QD + Dexamethasone 0.5 mg QD
-----------------------	--

#### Reporting group description:

Subjects received abiraterone acetate 1000 mg and dexamethasone 0.5 mg tablet orally QD up to 156 Weeks. Subjects who were progression-free at 156 weeks entered the extension phase of the study and received study treatment until death, radiographic disease progression and/or unequivocal clinical progression, and/or other specific reasons for discontinuation. Subjects who ended the extension phase prematurely and subjects who did not enter the extension phase entered a follow-up phase until end of study.

Reporting group values	Abiraterone Acetate 1000 mg QD + Prednisone 5 mg BID	Abiraterone Acetate 1000 mg QD + Prednisone 5 mg QD	Abiraterone Acetate 1000 mg QD + Prednisone 2.5 mg BID
Number of subjects	41	41	40
Title for AgeCategorical Units: subjects			
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	12	12	8
From 65 to 84 years	26	28	32
85 years and over	3	1	0
Title for AgeContinuous Units: years			
arithmetic mean	68.9	69	69.3
standard deviation	± 9.28	± 8.44	± 7.51
Title for Gender Units: subjects			
Male	41	41	40



Reporting group values	Abiraterone Acetate 1000 mg QD + Dexamethasone 0.5 mg QD	Total	
Number of subjects	42	164	
Title for AgeCategorical Units: subjects			
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	8	40	
From 65 to 84 years	32	118	
85 years and over	2	6	
Title for AgeContinuous Units: years			
arithmetic mean	71.3		
standard deviation	± 8.12	-	
Title for Gender Units: subjects			
Male	42	164	

## End points

### End points reporting groups

Reporting group title	Abiraterone Acetate 1000 mg QD + Prednisone 5 mg BID
Reporting group description: Subjects received abiraterone acetate 1000 milligram (mg) tablet orally once daily (QD) and prednisone 5 mg tablet orally twice daily (BID) up to 156 Weeks. Subjects who were progression-free at 156 weeks entered the extension phase of the study and received study treatment until death, radiographic disease progression and/or unequivocal clinical progression, and/or other specific reasons for discontinuation. Subjects who ended the extension phase prematurely and subjects who did not enter the extension phase entered a follow-up phase until end of study.	
Reporting group title	Abiraterone Acetate 1000 mg QD + Prednisone 5 mg QD
Reporting group description: Subjects received abiraterone acetate 1000 mg and prednisone 5 mg tablet orally QD up to 156 Weeks. Subjects who were progression-free at 156 weeks entered the extension phase of the study and received study treatment until death, radiographic disease progression and/or unequivocal clinical progression, and/or other specific reasons for discontinuation. Subjects who ended the extension phase prematurely and subjects who did not enter the extension phase entered a follow-up phase until end of study.	
Reporting group title	Abiraterone Acetate 1000 mg QD + Prednisone 2.5 mg BID
Reporting group description: Subjects received abiraterone acetate 1000 mg tablet orally QD and prednisone 2.5 mg tablet orally BID up to 156 Weeks. Subjects who were progression-free at 156 weeks entered the extension phase of the study and received study treatment until death, radiographic disease progression and/or unequivocal clinical progression, and/or other specific reasons for discontinuation. Subjects who ended the extension phase prematurely and subjects who did not enter the extension phase entered a follow-up phase until end of study.	
Reporting group title	Abiraterone Acetate 1000 mg QD + Dexamethasone 0.5 mg QD
Reporting group description: Subjects received abiraterone acetate 1000 mg and dexamethasone 0.5 mg tablet orally QD up to 156 Weeks. Subjects who were progression-free at 156 weeks entered the extension phase of the study and received study treatment until death, radiographic disease progression and/or unequivocal clinical progression, and/or other specific reasons for discontinuation. Subjects who ended the extension phase prematurely and subjects who did not enter the extension phase entered a follow-up phase until end of study.	

### Primary: Percentage of Subjects Experiencing Neither of the 2 Mineralocorticoid Excess Toxicity During the First 24 Weeks of Treatment

End point title	Percentage of Subjects Experiencing Neither of the 2 Mineralocorticoid Excess Toxicity During the First 24 Weeks of Treatment <sup>[1]</sup>
End point description: No mineralocorticoid excess is defined as experiencing neither of the 2 mineralocorticoid excess toxicities, that is, neither hypokalemia nor hypertension. Safety population included all randomized and treated subjects. Here "N" (Number of subjects analyzed) signifies those subjects who were evaluable for this endpoint.	
End point type	Primary
End point timeframe: Week 24	
Notes: [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Descriptive statistics were done, no inferential statistical analyses were performed.	

End point values	Abiraterone Acetate 1000 mg QD + Prednisone 5 mg BID	Abiraterone Acetate 1000 mg QD + Prednisone 5 mg QD	Abiraterone Acetate 1000 mg QD + Prednisone 2.5 mg BID	Abiraterone Acetate 1000 mg QD + Dexamethasone 0.5 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	34	38	35	37
Units: Percentage of subjects				
number (confidence interval 95%)				
Percentage of subjects	70.6 (53.8 to 83.2)	36.8 (23.4 to 52.7)	60.0 (43.6 to 74.4)	70.3 (54.2 to 82.5)

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of Subjects With Confirmed Prostate Specific Antigen (PSA) Response Rate [Greater Than or Equal to ( $\geq$ ) 50 Percent (%) Decline From Baseline] at Week 12

End point title	Percentage of Subjects With Confirmed Prostate Specific Antigen (PSA) Response Rate [Greater Than or Equal to ( $\geq$ ) 50 Percent (%) Decline From Baseline] at Week 12
End point description:	
The PSA response is defined as a $\geq$ 50% decline from baseline according to the adapted Prostate Cancer Working Group 2 (PCWG2) criteria. For a PSA response to be confirmed, an additional PSA measurement obtained 4 or more weeks later has to show $\geq$ 50% decline from baseline. Intent-to-treat (ITT) population included all randomized subjects regardless of whether they received any study treatment. Here "N" (Number of subjects analyzed) signifies those subjects who were evaluable for this endpoint.	
End point type	Secondary
End point timeframe:	
Week 12	

End point values	Abiraterone Acetate 1000 mg QD + Prednisone 5 mg BID	Abiraterone Acetate 1000 mg QD + Prednisone 5 mg QD	Abiraterone Acetate 1000 mg QD + Prednisone 2.5 mg BID	Abiraterone Acetate 1000 mg QD + Dexamethasone 0.5 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	35	34	36	39
Units: Percentage of subjects				
number (confidence interval 95%)	57.1 (39.4 to 73.7)	70.6 (52.5 to 84.9)	47.2 (30.4 to 64.5)	79.5 (63.5 to 90.7)

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change From Baseline to Endpoint in Brief Pain Inventory- Short Form

**(BPI-SF) Score: Worst Pain**

End point title	Change From Baseline to Endpoint in Brief Pain Inventory-Short Form (BPI-SF) Score: Worst Pain
-----------------	--

## End point description:

BPI-SF is 11-item self-reported questionnaire designed to assess severity and impact of pain on daily functions (pain interference). It includes 4 questions that assess pain intensity/severity (worst, least, average, right now) and 7 questions that assess impact of pain on daily functions (general activity, mood, walking ability, normal work, relations with other people, sleep, enjoyment of life). BPI-SF scores range from 0=No pain to 10=Pain as bad as you can imagine; Higher scores indicate greater pain. Worst pain item has scale of 0 to 10 with 0 indicating "No pain" and 10 indicating "Pain as bad as you can imagine". Last observation carried forward (LOCF) approach used for endpoint analysis. Last observation defined as last visit with non-missing data for parameter analyzed. ITT population included all randomized subjects regardless of whether they received any study treatment. Here "N" (Number of Subjects Analyzed) signifies those subjects who were evaluable for this endpoint.

End point type	Secondary
----------------	-----------

## End point timeframe:

Baseline up to the Endpoint (last post-baseline assessment value during 156 weeks of main study treatment period [MSTP])

End point values	Abiraterone Acetate 1000 mg QD + Prednisone 5 mg BID	Abiraterone Acetate 1000 mg QD + Prednisone 5 mg QD	Abiraterone Acetate 1000 mg QD + Prednisone 2.5 mg BID	Abiraterone Acetate 1000 mg QD + Dexamethasone 0.5 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	36	33	37	38
Units: Units on a scale				
arithmetic mean (standard deviation)	1.6 (± 2.43)	2.2 (± 2.86)	2.5 (± 2.39)	1.3 (± 2.28)

**Statistical analyses**

No statistical analyses for this end point

**Secondary: Change From Baseline to Endpoint in Brief Pain Inventory- Short Form (BPI-SF) Score: Pain Intensity Subscale**

End point title	Change From Baseline to Endpoint in Brief Pain Inventory-Short Form (BPI-SF) Score: Pain Intensity Subscale
-----------------	---

## End point description:

BPI-SF is 11-item self-reported questionnaire designed to assess severity and impact of pain on daily functions (pain interference). It includes 4 questions that assess pain intensity/severity (worst, least, average, right now) and 7 questions that assess impact of pain on daily functions (general activity, mood, walking ability, normal work, relations with other people, sleep, enjoyment of life). BPI-SF scores range from 0=No pain to 10=Pain as bad as you can imagine; Higher scores indicate greater pain. Pain Severity Index is the mean of 4 pain scores on BPI-SF; range is 0=No pain to 10=Pain as bad as you can imagine; Higher score indicates greater pain severity. LOCF approach used for endpoint analysis. Last observation defined as last visit with non-missing data for parameter analyzed. ITT population: all randomized subjects regardless of whether they received any study treatment. 'N' (number of subjects analyzed)- number of subjects who were evaluable for this endpoint.

End point type	Secondary
----------------	-----------

## End point timeframe:

Baseline up to the Endpoint (last post-baseline assessment value during 156 weeks of MSTP)

<b>End point values</b>	Abiraterone Acetate 1000 mg QD + Prednisone 5 mg BID	Abiraterone Acetate 1000 mg QD + Prednisone 5 mg QD	Abiraterone Acetate 1000 mg QD + Prednisone 2.5 mg BID	Abiraterone Acetate 1000 mg QD + Dexamethasone 0.5 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	37	35	37	38
Units: Units on a scale				
arithmetic mean (standard deviation)	1.31 (± 1.788)	1.37 (± 1.952)	1.80 (± 2.014)	0.97 (± 1.610)

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change From Baseline to Endpoint in Brief Pain Inventory- Short Form (BPI-SF) Score: Pain Interference Subscale

End point title	Change From Baseline to Endpoint in Brief Pain Inventory- Short Form (BPI-SF) Score: Pain Interference Subscale
-----------------	---

End point description:

BPI-SF is 11-item self-reported questionnaire designed to assess severity and impact of pain on daily functions (pain interference). It includes 4 questions that assess pain intensity/severity (worst, least, average, right now) and 7 questions that assess impact of pain on daily functions (general activity, mood, walking ability, normal work, relations with other people, sleep, enjoyment of life). BPI-SF scores range from 0=No pain to 10=Pain as bad as you can imagine; Higher scores indicate greater pain. Pain Interference Index is the mean of the scores for the 7 items of the BPI-SF; range is 0=Does not interfere to 10=Completely interferes. LOCF approach used for endpoint analysis. Last observation defined as last visit with non-missing data for parameter analyzed. ITT population: all randomized subjects regardless of whether they received any study treatment. 'N' (number of subjects analyzed)- number of subjects who were evaluable for this endpoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline up to the Endpoint (last post-baseline assessment value during 156 weeks of MSTP)

<b>End point values</b>	Abiraterone Acetate 1000 mg QD + Prednisone 5 mg BID	Abiraterone Acetate 1000 mg QD + Prednisone 5 mg QD	Abiraterone Acetate 1000 mg QD + Prednisone 2.5 mg BID	Abiraterone Acetate 1000 mg QD + Dexamethasone 0.5 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	32	30	35	37
Units: Units on a scale				
arithmetic mean (standard deviation)	0.89 (± 1.794)	1.76 (± 2.100)	1.52 (± 2.180)	1.12 (± 1.687)

## Statistical analyses

**Secondary: Change From Baseline to Endpoint in EuroQol-5 Dimension-5 Level (EQ-5D-5L): Index Score**

End point title	Change From Baseline to Endpoint in EuroQol-5 Dimension-5 Level (EQ-5D-5L): Index Score
-----------------	---

## End point description:

EQ-5D-5L measures health outcome self-completed by respondents. It consists of EQ-5D-5L descriptive system and EQ visual analogue scale (EQ-VAS). The descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each has 5 levels (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Subject selects answer for each of 5 dimensions considering response that best matches his/her health "today". Responses were used to generate a Health Status Index (HSI). HSI ranges from -0.148 to 0.949 and is anchored at 0 (health state value equal to dead) and 1 (full health). LOCF approach used for endpoint analysis. Last observation defined as last visit with non-missing data for parameter analyzed. ITT population: all randomized subjects regardless of whether they received any study treatment. 'N' (number of subjects analyzed)- number of subjects who were evaluable for this endpoint.

End point type	Secondary
----------------	-----------

## End point timeframe:

Baseline up to the Endpoint (last post-baseline assessment value during 156 weeks of MSTP)

End point values	Abiraterone Acetate 1000 mg QD + Prednisone 5 mg BID	Abiraterone Acetate 1000 mg QD + Prednisone 5 mg QD	Abiraterone Acetate 1000 mg QD + Prednisone 2.5 mg BID	Abiraterone Acetate 1000 mg QD + Dexamethasone 0.5 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	37	38	36	38
Units: Units on a scale				
arithmetic mean (standard deviation)	-0.0694 ( $\pm$ 0.18402)	-0.0638 ( $\pm$ 0.17772)	-0.0728 ( $\pm$ 0.18113)	-0.0359 ( $\pm$ 0.13515)

**Statistical analyses**

No statistical analyses for this end point

**Secondary: Change From Baseline to Endpoint in EuroQol-5 Dimension-5 Level (EQ-5D-5L): EQ-VAS**

End point title	Change From Baseline to Endpoint in EuroQol-5 Dimension-5 Level (EQ-5D-5L): EQ-VAS
-----------------	--

## End point description:

EQ-5D-5L measures health outcome self-completed by respondents. It consists of EQ-5D-5L descriptive system and EQ visual analogue scale (EQ-VAS). EQ-VAS self-rating records the respondent's own assessment of his/her overall health status at time of completion, on scale of 0 (the worst health you can imagine) to 100 (the best health you can imagine). LOCF approach used for endpoint analysis. Last observation defined as last visit with non-missing data for parameter analyzed. ITT population: all randomized subjects regardless of whether they received any study treatment. 'N' (number of subjects analyzed)- number of subjects who were evaluable for this endpoint.

End point type	Secondary
----------------	-----------

## End point timeframe:

Baseline up to the Endpoint (last post-baseline assessment value during 156 weeks of MSTP)

<b>End point values</b>	Abiraterone Acetate 1000 mg QD + Prednisone 5 mg BID	Abiraterone Acetate 1000 mg QD + Prednisone 5 mg QD	Abiraterone Acetate 1000 mg QD + Prednisone 2.5 mg BID	Abiraterone Acetate 1000 mg QD + Dexamethasone 0.5 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	38	37	37	37
Units: Units on a scale				
arithmetic mean (standard deviation)	-4.5 (± 18.11)	-5.0 (± 16.82)	-6.6 (± 15.09)	-3.1 (± 13.00)

### Statistical analyses

No statistical analyses for this end point

### Secondary: Change From Baseline to Endpoint in Functional Assessment of Cancer Therapy-Prostate (FACT-P) Questionnaire Score

End point title	Change From Baseline to Endpoint in Functional Assessment of Cancer Therapy-Prostate (FACT-P) Questionnaire Score
-----------------	---

End point description:

FACT-P is 39-item subject rated questionnaire consists of 5 subscales assessing physical well-being (7 items; score range 0-28), social/family well-being (7 items; score range 0-28), emotional well-being (6 items; score range 0-24), functional well-being (7 items; score range 0-28), prostate-specific concerns (12 items; score range 0-48). Each item rated on 0-4 Likert type scale and combined to produce subscale scores for each domain, as well as global QoL score that ranges from 0-156. Higher scores=better QoL. Additional Concerns subscale has 12 items, each with score 0-6 making total subscale range 0-72 (higher scores are better). Missing data imputed per FACT-P Ver4 scoring system (sum of item scores\*number of items in subscale/number of items answered). Last observation defined as last visit with non-missing data for parameter. ITT population analyzed. Here 'n'(number of subjects analyzed) signifies number of subjects analyzed in specific category.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline up to the Endpoint (last post-baseline assessment value during 156 weeks of MSTP)

<b>End point values</b>	Abiraterone Acetate 1000 mg QD + Prednisone 5 mg BID	Abiraterone Acetate 1000 mg QD + Prednisone 5 mg QD	Abiraterone Acetate 1000 mg QD + Prednisone 2.5 mg BID	Abiraterone Acetate 1000 mg QD + Dexamethasone 0.5 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	41	41	40	42
Units: Units on a scale				
arithmetic mean (standard deviation)				
Physical Well-Being(n=37,38,37,38)	-0.98 (± 3.930)	-2.20 (± 4.449)	-2.46 (± 4.124)	-1.04 (± 3.268)
Social/Family Well-Being (n=37,37,36,38)	-0.01 (± 3.679)	0.61 (± 3.794)	-0.78 (± 5.177)	-1.97 (± 5.749)
Emotional Well-Being (n=37,38,35,36)	-1.46 (± 4.785)	-0.89 (± 3.289)	-1.66 (± 3.915)	-0.02 (± 3.542)

Functional Well-Being (n=36,38,36,36)	-1.13 (± 4.575)	-2.19 (± 5.767)	-2.67 (± 5.957)	-2.95 (± 6.698)
Global Score (n=35,38,36,34)	-4.73 (± 18.248)	-6.62 (± 17.118)	-10.39 (± 20.798)	-5.77 (± 18.322)
Additional Concerns (n=37,38,37,38)	-1.29 (± 7.694)	-2.35 (± 6.342)	-3.96 (± 6.492)	-0.72 (± 6.080)

## Statistical analyses

No statistical analyses for this end point

## Secondary: Progression-Free Survival (PFS)

End point title	Progression-Free Survival (PFS)
End point description:	
PFS: Time from randomization to one of following: radiographic progression (RP), clinical progression (CP) or death. RP- per PCWG2 criteria and modified RECIST as time from randomization to one of following: 1) considered to have progressed by bone scan if: a) first scan with $\geq 2$ new lesions compared to baseline at $< 12$ weeks from randomization and confirmed by second scan $\geq 6$ weeks later with $\geq 2$ additional new lesions, b) first scan with $\geq 2$ new lesions compared to baseline at $\geq 12$ weeks from randomization and new lesions on next bone scan $\geq 6$ weeks later; 2) Progression of soft tissue lesions per modified RECIST; CP: cancer pain requiring initiation of chronic use of opiate or immediate need to initiate cytotoxic chemotherapy or either radiation therapy or surgical intervention for complications due to tumor progression, even in absence of RP, Or deterioration in ECOG performance status to grade 3 or above. Efficacy analysis set included ITT population.	
End point type	Secondary
End point timeframe:	
Up to 4.9 years	

End point values	Abiraterone Acetate 1000 mg QD + Prednisone 5 mg BID	Abiraterone Acetate 1000 mg QD + Prednisone 5 mg QD	Abiraterone Acetate 1000 mg QD + Prednisone 2.5 mg BID	Abiraterone Acetate 1000 mg QD + Dexamethasone 0.5 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	41	41	40	42
Units: Months				
median (confidence interval 95%)	16.16 (9.95 to 23.75)	12.68 (7.66 to 29.47)	8.51 (5.62 to 15.44)	21.22 (15.08 to 38.44)

## Statistical analyses

No statistical analyses for this end point

## Secondary: Time to Prostate-Specific Antigen (PSA) Progression

End point title	Time to Prostate-Specific Antigen (PSA) Progression
End point description:	
Time to PSA progression was defined as time interval from the date of randomization to the date of the first prostate-specific antigen (PSA) progression as defined in the protocol-specific Prostate Specific Antigen Working Group 2 (PSAWG2) criteria during the main study treatment period. PCWG2 defines	



PSA progression as the date that a 25 percent (%) or greater increase and an absolute increase of 2 nanogram per milliliter (ng/mL) or more from the nadir is documented, which is confirmed by a second value obtained 3 or more weeks later. Efficacy analysis set included ITT population- all randomized subjects regardless of whether they received any study treatment. '99999' indicates that upper limit of 95% Confidence Interval (CI) was not estimable due to a limited number of events and the small sample size.

End point type	Secondary
End point timeframe:	
Up to 156 weeks	

End point values	Abiraterone Acetate 1000 mg QD + Prednisone 5 mg BID	Abiraterone Acetate 1000 mg QD + Prednisone 5 mg QD	Abiraterone Acetate 1000 mg QD + Prednisone 2.5 mg BID	Abiraterone Acetate 1000 mg QD + Dexamethasone 0.5 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	41	41	40	42
Units: Months				
median (confidence interval 95%)	10.38 (10.05 to 20.99)	10.22 (7.39 to 26.84)	4.83 (2.79 to 10.15)	18.56 (10.15 to 99999)

## Statistical analyses

No statistical analyses for this end point

## Secondary: Objective Response Rate (ORR)

End point title	Objective Response Rate (ORR)
-----------------	-------------------------------

End point description:

ORR was defined as the percentage of subjects with measurable disease at baseline achieving a complete response (CR) or partial response (PR) according to modified response evaluation criteria in solid tumors (RECIST) criteria. RECIST criteria for CR: disappearance of all target lesions and non-target lesions, any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm and normalization of tumor marker level. All lymph nodes must be non-pathological in size (<10 millimetre [mm] short axis). PR: At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. Efficacy analysis set included ITT population- all randomized subjects regardless of whether they received any study treatment. Population included subjects with measurable disease at baseline.

End point type	Secondary
End point timeframe:	
Up to 4.9 years	

End point values	Abiraterone Acetate 1000 mg QD + Prednisone 5 mg BID	Abiraterone Acetate 1000 mg QD + Prednisone 5 mg QD	Abiraterone Acetate 1000 mg QD + Prednisone 2.5 mg BID	Abiraterone Acetate 1000 mg QD + Dexamethasone 0.5 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	19	18	10	16
Units: Percentage of subjects				
number (not applicable)	42.1	38.9	60.0	56.3

## Statistical analyses

No statistical analyses for this end point

### Secondary: Time to Opiate Use for Cancer-related Pain

End point title	Time to Opiate Use for Cancer-related Pain
-----------------	--

End point description:

Time to opiate use for cancer-related pain is defined the time interval from the date of randomization to the first date of opiate use for cancer pain. Efficacy analysis set included ITT population- all randomized subjects regardless of whether they received any study treatment. '99999' indicates that median and 95% Confidence Interval (CI) were not estimable due to a limited number of events and the small sample size.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 156 weeks

End point values	Abiraterone Acetate 1000 mg QD + Prednisone 5 mg BID	Abiraterone Acetate 1000 mg QD + Prednisone 5 mg QD	Abiraterone Acetate 1000 mg QD + Prednisone 2.5 mg BID	Abiraterone Acetate 1000 mg QD + Dexamethasone 0.5 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	41	41	40	42
Units: Months				
median (confidence interval 95%)	99999 (99999 to 99999)	99999 (99999 to 99999)	99999 (99999 to 99999)	99999 (99999 to 99999)

## Statistical analyses

No statistical analyses for this end point

### Secondary: Time to Deterioration in Eastern Cooperative Oncology Group (ECOG) Performance Score by 1 Point

End point title	Time to Deterioration in Eastern Cooperative Oncology Group (ECOG) Performance Score by 1 Point
-----------------	---

End point description:

Time to deterioration in ECOG Performance Status, the time interval from the date of randomization to the first date in which at least one point change (worsening) in the ECOG is observed during the main study treatment period. The ECOG performance status is a grade scale to measure quality of life (QoL). Scores run from 0 to 5, with 0 denoting perfect health and 5 denoting death. Efficacy analysis set included ITT population- all randomized subjects regardless of whether they received any study treatment. '99999' indicates that median and 95% Confidence Interval (CI) was not estimable due to a limited number of events and the small sample size.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 156 weeks

End point values	Abiraterone Acetate 1000 mg QD + Prednisone 5 mg BID	Abiraterone Acetate 1000 mg QD + Prednisone 5 mg QD	Abiraterone Acetate 1000 mg QD + Prednisone 2.5 mg BID	Abiraterone Acetate 1000 mg QD + Dexamethasone 0.5 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	41	41	40	42
Units: Months				
median (confidence interval 95%)	99999 (99999 to 99999)	99999 (99999 to 99999)	99999 (99999 to 99999)	99999 (23.95 to 99999)

### Statistical analyses

No statistical analyses for this end point

### Secondary: Overall Survival

End point title	Overall Survival
-----------------	------------------

End point description:

Overall survival was defined as the time interval from the date of randomization to the date of death from any cause. Efficacy analysis set included ITT population- all randomized subjects regardless of whether they received any study treatment. Here '99999' indicates that median and upper limit of 95% Confidence Interval (CI) was not estimable due to a limited number of events and the small sample size.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 4.9 years

End point values	Abiraterone Acetate 1000 mg QD + Prednisone 5 mg BID	Abiraterone Acetate 1000 mg QD + Prednisone 5 mg QD	Abiraterone Acetate 1000 mg QD + Prednisone 2.5 mg BID	Abiraterone Acetate 1000 mg QD + Dexamethasone 0.5 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	41	41	40	42
Units: Months				
median (confidence interval 95%)	34.07 (26.38 to 48.49)	48.43 (39.95 to 99999)	27.96 (23.66 to 40.51)	42.81 (30.23 to 99999)

### Statistical analyses

No statistical analyses for this end point

### Secondary: Time to Next Prostate Cancer Therapy

End point title	Time to Next Prostate Cancer Therapy
End point description:	
Time to next prostate cancer therapy is defined as the time interval from the date of randomization to the date of initiation of first next therapy for prostate cancer. Efficacy analysis set included ITT population- all randomized subjects regardless of whether they received any study treatment.	
End point type	Secondary
End point timeframe:	
Up to 4.9 years	

End point values	Abiraterone Acetate 1000 mg QD + Prednisone 5 mg BID	Abiraterone Acetate 1000 mg QD + Prednisone 5 mg QD	Abiraterone Acetate 1000 mg QD + Prednisone 2.5 mg BID	Abiraterone Acetate 1000 mg QD + Dexamethasone 0.5 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	41	41	40	42
Units: Months				
median (confidence interval 95%)	20.14 (13.27 to 26.91)	19.48 (12.09 to 33.08)	16.66 (9.26 to 22.47)	28.29 (20.83 to 38.90)

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Up to 4.9 years

Adverse event reporting additional description:

Safety population included all randomized and treated subjects.

Assessment type	Non-systematic
-----------------	----------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	20.0
--------------------	------

### Reporting groups

Reporting group title	Abiraterone Acetate 1000 mg QD + Prednisone 5 mg BID
-----------------------	--

Reporting group description:

Subjects received abiraterone acetate 1000 milligram (mg) tablet orally once daily (QD) and prednisone 5 mg tablet orally twice daily (BID) up to 156 Weeks. Subjects who were progression-free at 156 weeks entered the extension phase of the study and received study treatment until death, radiographic disease progression and/or unequivocal clinical progression, and/or other specific reasons for discontinuation. Subjects who ended the extension phase prematurely and subjects who did not enter the extension phase entered a follow-up phase until end of study.

Reporting group title	Abiraterone Acetate 1000 mg QD + Prednisone 5 mg QD
-----------------------	---

Reporting group description:

Subjects received abiraterone acetate 1000 mg and prednisone 5 mg tablet orally QD up to 156 Weeks. Subjects who were progression-free at 156 weeks entered the extension phase of the study and received study treatment until death, radiographic disease progression and/or unequivocal clinical progression, and/or other specific reasons for discontinuation. Subjects who ended the extension phase prematurely and subjects who did not enter the extension phase entered a follow-up phase until end of study.

Reporting group title	Abiraterone Acetate 1000 mg QD + Prednisone 2.5 mg BID
-----------------------	--

Reporting group description:

Subjects received abiraterone acetate 1000 mg tablet orally QD and prednisone 2.5 mg tablet orally BID up to 156 Weeks. Subjects who were progression free at 156 weeks entered the extension phase of the study and received study treatment until death, radiographic disease progression and/or unequivocal clinical progression, and/or other specific reasons for discontinuation. Subjects who ended the extension phase prematurely and subjects who did not enter the extension phase entered a follow-up phase until end of study.

Reporting group title	Abiraterone Acetate 1000 mg QD + Dexamethasone 0.5 mg QD
-----------------------	--

Reporting group description:

Subjects received abiraterone acetate 1000 mg and dexamethasone 0.5 mg tablet orally QD up to 156 Weeks. Subjects who were progression free at 156 weeks entered the extension phase of the study and received study treatment until death, radiographic disease progression and/or unequivocal clinical progression, and/or other specific reasons for discontinuation. Subjects who ended the extension phase prematurely and subjects who did not enter the extension phase entered a follow-up phase until end of study.

Serious adverse events	Abiraterone Acetate 1000 mg QD + Prednisone 5 mg BID	Abiraterone Acetate 1000 mg QD + Prednisone 5 mg QD	Abiraterone Acetate 1000 mg QD + Prednisone 2.5 mg BID
Total subjects affected by serious adverse events			
subjects affected / exposed	12 / 41 (29.27%)	10 / 41 (24.39%)	11 / 39 (28.21%)
number of deaths (all causes)	25	15	26
number of deaths resulting from			

adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Myelodysplastic Syndrome			
subjects affected / exposed	0 / 41 (0.00%)	0 / 41 (0.00%)	0 / 39 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neuroendocrine Carcinoma of the Skin			
subjects affected / exposed	0 / 41 (0.00%)	0 / 41 (0.00%)	0 / 39 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Circulatory Collapse			
subjects affected / exposed	0 / 41 (0.00%)	0 / 41 (0.00%)	1 / 39 (2.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Deep Vein Thrombosis			
subjects affected / exposed	0 / 41 (0.00%)	0 / 41 (0.00%)	1 / 39 (2.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Death			
subjects affected / exposed	0 / 41 (0.00%)	1 / 41 (2.44%)	0 / 39 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
General Physical Health Deterioration			
subjects affected / exposed	1 / 41 (2.44%)	0 / 41 (0.00%)	0 / 39 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Performance Status Decreased			
subjects affected / exposed	1 / 41 (2.44%)	0 / 41 (0.00%)	0 / 39 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			

subjects affected / exposed	0 / 41 (0.00%)	1 / 41 (2.44%)	0 / 39 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	1 / 41 (2.44%)	0 / 41 (0.00%)	0 / 39 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Pelvic Pain			
subjects affected / exposed	1 / 41 (2.44%)	0 / 41 (0.00%)	0 / 39 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Pleural Effusion			
subjects affected / exposed	0 / 41 (0.00%)	1 / 41 (2.44%)	0 / 39 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory Failure			
subjects affected / exposed	0 / 41 (0.00%)	0 / 41 (0.00%)	1 / 39 (2.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Psychiatric disorders			
Psychotic Disorder			
subjects affected / exposed	0 / 41 (0.00%)	0 / 41 (0.00%)	0 / 39 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Product issues			
Device Occlusion			
subjects affected / exposed	1 / 41 (2.44%)	0 / 41 (0.00%)	0 / 39 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			

Fall			
subjects affected / exposed	0 / 41 (0.00%)	0 / 41 (0.00%)	0 / 39 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Joint Injury			
subjects affected / exposed	0 / 41 (0.00%)	1 / 41 (2.44%)	0 / 39 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Atrial Flutter			
subjects affected / exposed	0 / 41 (0.00%)	1 / 41 (2.44%)	0 / 39 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrioventricular Block Second Degree			
subjects affected / exposed	0 / 41 (0.00%)	0 / 41 (0.00%)	1 / 39 (2.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bradycardia			
subjects affected / exposed	1 / 41 (2.44%)	0 / 41 (0.00%)	0 / 39 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac Failure			
subjects affected / exposed	0 / 41 (0.00%)	0 / 41 (0.00%)	1 / 39 (2.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ventricular Arrhythmia			
subjects affected / exposed	0 / 41 (0.00%)	0 / 41 (0.00%)	1 / 39 (2.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Nervous system disorders			
Aphasia			
subjects affected / exposed	0 / 41 (0.00%)	1 / 41 (2.44%)	0 / 39 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0



Cerebral Infarction			
subjects affected / exposed	0 / 41 (0.00%)	0 / 41 (0.00%)	0 / 39 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dementia Alzheimer's Type			
subjects affected / exposed	0 / 41 (0.00%)	1 / 41 (2.44%)	0 / 39 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dizziness Postural			
subjects affected / exposed	0 / 41 (0.00%)	0 / 41 (0.00%)	0 / 39 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Frontotemporal Dementia			
subjects affected / exposed	0 / 41 (0.00%)	0 / 41 (0.00%)	0 / 39 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhage Intracranial			
subjects affected / exposed	0 / 41 (0.00%)	0 / 41 (0.00%)	1 / 39 (2.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoaesthesia			
subjects affected / exposed	0 / 41 (0.00%)	1 / 41 (2.44%)	0 / 39 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypokinesia			
subjects affected / exposed	0 / 41 (0.00%)	0 / 41 (0.00%)	1 / 39 (2.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nerve Root Compression			
subjects affected / exposed	0 / 41 (0.00%)	0 / 41 (0.00%)	1 / 39 (2.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal Cord Compression			

subjects affected / exposed	2 / 41 (4.88%)	1 / 41 (2.44%)	0 / 39 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	0 / 41 (0.00%)	1 / 41 (2.44%)	1 / 39 (2.56%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia of Malignant Disease			
subjects affected / exposed	1 / 41 (2.44%)	0 / 41 (0.00%)	0 / 39 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutropenia			
subjects affected / exposed	0 / 41 (0.00%)	1 / 41 (2.44%)	0 / 39 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Vision Blurred			
subjects affected / exposed	0 / 41 (0.00%)	0 / 41 (0.00%)	1 / 39 (2.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal Pain			
subjects affected / exposed	0 / 41 (0.00%)	1 / 41 (2.44%)	0 / 39 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	0 / 41 (0.00%)	2 / 41 (4.88%)	0 / 39 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematochezia			
subjects affected / exposed	0 / 41 (0.00%)	0 / 41 (0.00%)	0 / 39 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Incarcerated Inguinal Hernia			
subjects affected / exposed	0 / 41 (0.00%)	0 / 41 (0.00%)	1 / 39 (2.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal Hernia			
subjects affected / exposed	0 / 41 (0.00%)	0 / 41 (0.00%)	1 / 39 (2.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Melaena			
subjects affected / exposed	0 / 41 (0.00%)	0 / 41 (0.00%)	0 / 39 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Obstructive Pancreatitis			
subjects affected / exposed	0 / 41 (0.00%)	1 / 41 (2.44%)	0 / 39 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatic Cyst			
subjects affected / exposed	0 / 41 (0.00%)	1 / 41 (2.44%)	0 / 39 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis			
subjects affected / exposed	0 / 41 (0.00%)	1 / 41 (2.44%)	0 / 39 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis Acute			
subjects affected / exposed	0 / 41 (0.00%)	1 / 41 (2.44%)	0 / 39 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 41 (0.00%)	1 / 41 (2.44%)	0 / 39 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			

Acute Kidney Injury			
subjects affected / exposed	0 / 41 (0.00%)	1 / 41 (2.44%)	0 / 39 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bladder Tamponade			
subjects affected / exposed	0 / 41 (0.00%)	1 / 41 (2.44%)	0 / 39 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematuria			
subjects affected / exposed	0 / 41 (0.00%)	0 / 41 (0.00%)	1 / 39 (2.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal Colic			
subjects affected / exposed	0 / 41 (0.00%)	0 / 41 (0.00%)	1 / 39 (2.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary Retention			
subjects affected / exposed	0 / 41 (0.00%)	0 / 41 (0.00%)	1 / 39 (2.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary Tract Obstruction			
subjects affected / exposed	0 / 41 (0.00%)	0 / 41 (0.00%)	1 / 39 (2.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Arthropathy			
subjects affected / exposed	0 / 41 (0.00%)	1 / 41 (2.44%)	0 / 39 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Back Pain			
subjects affected / exposed	0 / 41 (0.00%)	2 / 41 (4.88%)	1 / 39 (2.56%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Flank Pain			
subjects affected / exposed	0 / 41 (0.00%)	0 / 41 (0.00%)	0 / 39 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intervertebral Disc Protrusion			
subjects affected / exposed	0 / 41 (0.00%)	0 / 41 (0.00%)	1 / 39 (2.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mobility Decreased			
subjects affected / exposed	0 / 41 (0.00%)	0 / 41 (0.00%)	1 / 39 (2.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteoarthritis			
subjects affected / exposed	2 / 41 (4.88%)	0 / 41 (0.00%)	0 / 39 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pathological Fracture			
subjects affected / exposed	0 / 41 (0.00%)	1 / 41 (2.44%)	0 / 39 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Diverticulitis			
subjects affected / exposed	0 / 41 (0.00%)	0 / 41 (0.00%)	0 / 39 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower Respiratory Tract Infection			
subjects affected / exposed	0 / 41 (0.00%)	0 / 41 (0.00%)	1 / 39 (2.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 41 (0.00%)	0 / 41 (0.00%)	1 / 39 (2.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Sepsis			

subjects affected / exposed	0 / 41 (0.00%)	1 / 41 (2.44%)	0 / 39 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary Tract Infection			
subjects affected / exposed	0 / 41 (0.00%)	0 / 41 (0.00%)	1 / 39 (2.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Hypokalaemia			
subjects affected / exposed	0 / 41 (0.00%)	1 / 41 (2.44%)	0 / 39 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	1 / 41 (2.44%)	0 / 41 (0.00%)	0 / 39 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ketosis			
subjects affected / exposed	0 / 41 (0.00%)	0 / 41 (0.00%)	0 / 39 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Abiraterone Acetate 1000 mg QD + Dexamethasone 0.5 mg QD		
Total subjects affected by serious adverse events			
subjects affected / exposed	18 / 42 (42.86%)		
number of deaths (all causes)	20		
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Myelodysplastic Syndrome			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Neuroendocrine Carcinoma of the Skin			

subjects affected / exposed	1 / 42 (2.38%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Vascular disorders			
Circulatory Collapse			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Deep Vein Thrombosis			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Death			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
General Physical Health Deterioration			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Performance Status Decreased			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pyrexia			
subjects affected / exposed	2 / 42 (4.76%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Reproductive system and breast disorders			
Pelvic Pain			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Pleural Effusion			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory Failure			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Psychiatric disorders			
Psychotic Disorder			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Product issues			
Device Occlusion			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Joint Injury			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			



Atrial Flutter			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Atrioventricular Block Second Degree			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bradycardia			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac Failure			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ventricular Arrhythmia			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Aphasia			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cerebral Infarction			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Dementia Alzheimer's Type			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Dizziness Postural			

subjects affected / exposed	1 / 42 (2.38%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Frontotemporal Dementia			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Haemorrhage Intracranial			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypoaesthesia			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypokinesia			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nerve Root Compression			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Spinal Cord Compression			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Syncope			
subjects affected / exposed	3 / 42 (7.14%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
Anaemia of Malignant Disease			

subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Neutropenia			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Eye disorders			
Vision Blurred			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Abdominal Pain			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Diarrhoea			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Haematochezia			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Incarcerated Inguinal Hernia			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Inguinal Hernia			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Melaena			

subjects affected / exposed	1 / 42 (2.38%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Obstructive Pancreatitis			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pancreatic Cyst			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pancreatitis			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pancreatitis Acute			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vomiting			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Acute Kidney Injury			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Bladder Tamponade			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Haematuria			

subjects affected / exposed	2 / 42 (4.76%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Renal Colic			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Urinary Retention			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Urinary Tract Obstruction			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Arthropathy			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Back Pain			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Flank Pain			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Intervertebral Disc Protrusion			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Mobility Decreased			

subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Osteoarthritis			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pathological Fracture			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Diverticulitis			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Lower Respiratory Tract Infection			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pneumonia			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Sepsis			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Urinary Tract Infection			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			

Hypokalaemia			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hyponatraemia			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ketosis			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	<b>Abiraterone Acetate 1000 mg QD + Prednisone 5 mg BID</b>	<b>Abiraterone Acetate 1000 mg QD + Prednisone 5 mg QD</b>	<b>Abiraterone Acetate 1000 mg QD + Prednisone 2.5 mg BID</b>
Total subjects affected by non-serious adverse events			
subjects affected / exposed	39 / 41 (95.12%)	36 / 41 (87.80%)	37 / 39 (94.87%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Basal Cell Carcinoma			
subjects affected / exposed	3 / 41 (7.32%)	0 / 41 (0.00%)	0 / 39 (0.00%)
occurrences (all)	3	0	0
Vascular disorders			
Hot Flush			
subjects affected / exposed	3 / 41 (7.32%)	1 / 41 (2.44%)	3 / 39 (7.69%)
occurrences (all)	3	1	3
Hypertension			
subjects affected / exposed	14 / 41 (34.15%)	22 / 41 (53.66%)	13 / 39 (33.33%)
occurrences (all)	30	47	21
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	3 / 41 (7.32%)	4 / 41 (9.76%)	1 / 39 (2.56%)
occurrences (all)	6	8	1
Chest Pain			

subjects affected / exposed	0 / 41 (0.00%)	3 / 41 (7.32%)	1 / 39 (2.56%)
occurrences (all)	0	3	2
Fatigue			
subjects affected / exposed	2 / 41 (4.88%)	6 / 41 (14.63%)	5 / 39 (12.82%)
occurrences (all)	2	11	5
Influenza Like Illness			
subjects affected / exposed	3 / 41 (7.32%)	0 / 41 (0.00%)	0 / 39 (0.00%)
occurrences (all)	5	0	0
Oedema Peripheral			
subjects affected / exposed	8 / 41 (19.51%)	4 / 41 (9.76%)	4 / 39 (10.26%)
occurrences (all)	10	5	5
Pyrexia			
subjects affected / exposed	1 / 41 (2.44%)	1 / 41 (2.44%)	2 / 39 (5.13%)
occurrences (all)	1	1	3
Reproductive system and breast disorders			
Pelvic Pain			
subjects affected / exposed	3 / 41 (7.32%)	2 / 41 (4.88%)	0 / 39 (0.00%)
occurrences (all)	7	2	0
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	2 / 41 (4.88%)	1 / 41 (2.44%)	3 / 39 (7.69%)
occurrences (all)	2	1	3
Investigations			
Alanine Aminotransferase Increased			
subjects affected / exposed	3 / 41 (7.32%)	2 / 41 (4.88%)	3 / 39 (7.69%)
occurrences (all)	12	2	3
Aspartate Aminotransferase Increased			
subjects affected / exposed	1 / 41 (2.44%)	2 / 41 (4.88%)	3 / 39 (7.69%)
occurrences (all)	6	2	4
Blood Alkaline Phosphatase Increased			
subjects affected / exposed	1 / 41 (2.44%)	1 / 41 (2.44%)	1 / 39 (2.56%)
occurrences (all)	1	1	1
Blood Bilirubin Increased			



subjects affected / exposed	3 / 41 (7.32%)	0 / 41 (0.00%)	1 / 39 (2.56%)
occurrences (all)	3	0	2
Blood Lactate Dehydrogenase Increased			
subjects affected / exposed	0 / 41 (0.00%)	0 / 41 (0.00%)	2 / 39 (5.13%)
occurrences (all)	0	0	2
C-Reactive Protein Increased			
subjects affected / exposed	0 / 41 (0.00%)	0 / 41 (0.00%)	2 / 39 (5.13%)
occurrences (all)	0	0	2
Hepatic Enzyme Increased			
subjects affected / exposed	0 / 41 (0.00%)	0 / 41 (0.00%)	0 / 39 (0.00%)
occurrences (all)	0	0	0
Weight Decreased			
subjects affected / exposed	7 / 41 (17.07%)	7 / 41 (17.07%)	10 / 39 (25.64%)
occurrences (all)	11	9	12
Weight Increased			
subjects affected / exposed	4 / 41 (9.76%)	2 / 41 (4.88%)	1 / 39 (2.56%)
occurrences (all)	6	4	1
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	3 / 41 (7.32%)	0 / 41 (0.00%)	0 / 39 (0.00%)
occurrences (all)	3	0	0
Nervous system disorders			
Headache			
subjects affected / exposed	2 / 41 (4.88%)	2 / 41 (4.88%)	2 / 39 (5.13%)
occurrences (all)	2	2	3
Paraesthesia			
subjects affected / exposed	0 / 41 (0.00%)	0 / 41 (0.00%)	2 / 39 (5.13%)
occurrences (all)	0	0	2
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 41 (2.44%)	1 / 41 (2.44%)	1 / 39 (2.56%)
occurrences (all)	1	1	1
Gastrointestinal disorders			
Abdominal Pain			
subjects affected / exposed	4 / 41 (9.76%)	2 / 41 (4.88%)	1 / 39 (2.56%)
occurrences (all)	5	3	1

Abdominal Pain Upper subjects affected / exposed occurrences (all)	2 / 41 (4.88%) 2	1 / 41 (2.44%) 1	3 / 39 (7.69%) 3
Constipation subjects affected / exposed occurrences (all)	9 / 41 (21.95%) 9	4 / 41 (9.76%) 5	3 / 39 (7.69%) 4
Diarrhoea subjects affected / exposed occurrences (all)	3 / 41 (7.32%) 3	3 / 41 (7.32%) 8	2 / 39 (5.13%) 2
Dry Mouth subjects affected / exposed occurrences (all)	1 / 41 (2.44%) 1	0 / 41 (0.00%) 0	2 / 39 (5.13%) 2
Nausea subjects affected / exposed occurrences (all)	1 / 41 (2.44%) 1	2 / 41 (4.88%) 3	2 / 39 (5.13%) 2
Vomiting subjects affected / exposed occurrences (all)	2 / 41 (4.88%) 2	2 / 41 (4.88%) 2	2 / 39 (5.13%) 2
Skin and subcutaneous tissue disorders			
Hyperhidrosis subjects affected / exposed occurrences (all)	2 / 41 (4.88%) 2	0 / 41 (0.00%) 0	3 / 39 (7.69%) 3
Skin Atrophy subjects affected / exposed occurrences (all)	0 / 41 (0.00%) 0	0 / 41 (0.00%) 0	0 / 39 (0.00%) 0
Renal and urinary disorders			
Haematuria subjects affected / exposed occurrences (all)	2 / 41 (4.88%) 3	1 / 41 (2.44%) 1	2 / 39 (5.13%) 3
Urinary Retention subjects affected / exposed occurrences (all)	2 / 41 (4.88%) 2	3 / 41 (7.32%) 3	0 / 39 (0.00%) 0
Musculoskeletal and connective tissue disorders			
Arthralgia subjects affected / exposed occurrences (all)	9 / 41 (21.95%) 14	9 / 41 (21.95%) 12	2 / 39 (5.13%) 2

Back Pain			
subjects affected / exposed	13 / 41 (31.71%)	5 / 41 (12.20%)	10 / 39 (25.64%)
occurrences (all)	16	8	13
Bone Pain			
subjects affected / exposed	11 / 41 (26.83%)	3 / 41 (7.32%)	5 / 39 (12.82%)
occurrences (all)	14	4	7
Groin Pain			
subjects affected / exposed	1 / 41 (2.44%)	0 / 41 (0.00%)	2 / 39 (5.13%)
occurrences (all)	1	0	3
Muscle Spasms			
subjects affected / exposed	4 / 41 (9.76%)	1 / 41 (2.44%)	4 / 39 (10.26%)
occurrences (all)	7	1	4
Musculoskeletal Pain			
subjects affected / exposed	3 / 41 (7.32%)	1 / 41 (2.44%)	2 / 39 (5.13%)
occurrences (all)	3	1	3
Myalgia			
subjects affected / exposed	2 / 41 (4.88%)	5 / 41 (12.20%)	0 / 39 (0.00%)
occurrences (all)	2	5	0
Osteopenia			
subjects affected / exposed	3 / 41 (7.32%)	3 / 41 (7.32%)	0 / 39 (0.00%)
occurrences (all)	3	3	0
Osteoporosis			
subjects affected / exposed	1 / 41 (2.44%)	1 / 41 (2.44%)	1 / 39 (2.56%)
occurrences (all)	1	1	1
Pain in Extremity			
subjects affected / exposed	5 / 41 (12.20%)	2 / 41 (4.88%)	4 / 39 (10.26%)
occurrences (all)	6	2	7
Infections and infestations			
Bronchitis			
subjects affected / exposed	0 / 41 (0.00%)	2 / 41 (4.88%)	0 / 39 (0.00%)
occurrences (all)	0	2	0
Nasopharyngitis			
subjects affected / exposed	3 / 41 (7.32%)	1 / 41 (2.44%)	3 / 39 (7.69%)
occurrences (all)	3	1	5
Urinary Tract Infection			

subjects affected / exposed occurrences (all)	1 / 41 (2.44%) 1	4 / 41 (9.76%) 5	0 / 39 (0.00%) 0
Metabolism and nutrition disorders Decreased Appetite subjects affected / exposed occurrences (all)	1 / 41 (2.44%) 2	1 / 41 (2.44%) 1	2 / 39 (5.13%) 2
Hypokalaemia subjects affected / exposed occurrences (all)	5 / 41 (12.20%) 6	7 / 41 (17.07%) 13	7 / 39 (17.95%) 9

<b>Non-serious adverse events</b>	Abiraterone Acetate 1000 mg QD + Dexamethasone 0.5 mg QD		
Total subjects affected by non-serious adverse events subjects affected / exposed	39 / 42 (92.86%)		
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Basal Cell Carcinoma subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0		
Vascular disorders Hot Flush subjects affected / exposed occurrences (all)  Hypertension subjects affected / exposed occurrences (all)	5 / 42 (11.90%) 6  10 / 42 (23.81%) 16		
General disorders and administration site conditions Asthenia subjects affected / exposed occurrences (all)  Chest Pain subjects affected / exposed occurrences (all)  Fatigue subjects affected / exposed occurrences (all)  Influenza Like Illness	1 / 42 (2.38%) 1  1 / 42 (2.38%) 1  7 / 42 (16.67%) 7		

subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		
Oedema Peripheral			
subjects affected / exposed	8 / 42 (19.05%)		
occurrences (all)	12		
Pyrexia			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences (all)	1		
Reproductive system and breast disorders			
Pelvic Pain			
subjects affected / exposed	2 / 42 (4.76%)		
occurrences (all)	2		
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		
Investigations			
Alanine Aminotransferase Increased			
subjects affected / exposed	5 / 42 (11.90%)		
occurrences (all)	10		
Aspartate Aminotransferase Increased			
subjects affected / exposed	4 / 42 (9.52%)		
occurrences (all)	7		
Blood Alkaline Phosphatase Increased			
subjects affected / exposed	3 / 42 (7.14%)		
occurrences (all)	4		
Blood Bilirubin Increased			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		
Blood Lactate Dehydrogenase Increased			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		
C-Reactive Protein Increased			

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Hepatic Enzyme Increased</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Weight Decreased</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Weight Increased</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 42 (0.00%)</p> <p>0</p> <p>3 / 42 (7.14%)</p> <p>13</p> <p>3 / 42 (7.14%)</p> <p>3</p> <p>6 / 42 (14.29%)</p> <p>8</p>		
<p>Injury, poisoning and procedural complications</p> <p>Fall</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>2 / 42 (4.76%)</p> <p>4</p>		
<p>Nervous system disorders</p> <p>Headache</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Paraesthesia</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>3 / 42 (7.14%)</p> <p>3</p> <p>2 / 42 (4.76%)</p> <p>2</p>		
<p>Blood and lymphatic system disorders</p> <p>Anaemia</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>4 / 42 (9.52%)</p> <p>5</p>		
<p>Gastrointestinal disorders</p> <p>Abdominal Pain</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Abdominal Pain Upper</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Constipation</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 42 (0.00%)</p> <p>0</p> <p>2 / 42 (4.76%)</p> <p>2</p> <p>2 / 42 (4.76%)</p> <p>2</p>		

Diarrhoea subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 2		
Dry Mouth subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0		
Nausea subjects affected / exposed occurrences (all)	3 / 42 (7.14%) 3		
Vomiting subjects affected / exposed occurrences (all)	2 / 42 (4.76%) 2		
Skin and subcutaneous tissue disorders Hyperhidrosis subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 2		
Skin Atrophy subjects affected / exposed occurrences (all)	3 / 42 (7.14%) 3		
Renal and urinary disorders Haematuria subjects affected / exposed occurrences (all)	3 / 42 (7.14%) 3		
Urinary Retention subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1		
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)	2 / 42 (4.76%) 2		
Back Pain subjects affected / exposed occurrences (all)	9 / 42 (21.43%) 13		
Bone Pain subjects affected / exposed occurrences (all)	2 / 42 (4.76%) 2		

Groin Pain			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		
Muscle Spasms			
subjects affected / exposed	2 / 42 (4.76%)		
occurrences (all)	3		
Musculoskeletal Pain			
subjects affected / exposed	2 / 42 (4.76%)		
occurrences (all)	3		
Myalgia			
subjects affected / exposed	0 / 42 (0.00%)		
occurrences (all)	0		
Osteopenia			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences (all)	1		
Osteoporosis			
subjects affected / exposed	3 / 42 (7.14%)		
occurrences (all)	3		
Pain in Extremity			
subjects affected / exposed	3 / 42 (7.14%)		
occurrences (all)	4		
Infections and infestations			
Bronchitis			
subjects affected / exposed	3 / 42 (7.14%)		
occurrences (all)	4		
Nasopharyngitis			
subjects affected / exposed	2 / 42 (4.76%)		
occurrences (all)	2		
Urinary Tract Infection			
subjects affected / exposed	3 / 42 (7.14%)		
occurrences (all)	3		
Metabolism and nutrition disorders			
Decreased Appetite			
subjects affected / exposed	1 / 42 (2.38%)		
occurrences (all)	1		
Hypokalaemia			



subjects affected / exposed	7 / 42 (16.67%)		
occurrences (all)	11		

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
13 November 2013	Amendment INT-2 included following changes: Adjusted inclusion/exclusion criteria to include subjects with liver or lung visceral metastases, subjects treated with a maximum of 2 anti-hypertensives, and subjects who previously received palliative radiotherapy for prostate cancer; adjusted exclusion criteria to exclude subjects who received prior corticosteroid treatment for prostate cancer; modified birth control requirements during the study; clarified procedural aspects of the study, including definitions of study completion and procedures associated with discontinuation; clarified concomitant therapy during the main study treatment period and extension phase.
27 November 2014	Amendment INT-4 included following changes: Referenced additional information on potential drug-drug interactions, including those related to CYP1A2, CYP2D6, and CYP2C8; clarified the scope and timing of data analyses; described dosing compliance procedures.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

Study not designed/powerd to allow comparisons in study groups. Per protocol amendment 6, the study was ended earlier since sufficient extension and follow-up data have been collected to allow statistical analysis of secondary objectives.

Notes: